or Try an Advanced Search...

    Technical Analysis for YMAB - Y-mAbs Therapeutics, Inc.

    Grade Last Price % Change Price Change
    D 14.71 -0.88% -0.13
    YMAB closed down 0.88 percent on Friday, April 26, 2024, on 52 percent of normal volume.
    Earnings due: May 7
    *** please verify all earnings dates ***
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Down
    Historical YMAB trend table...
    Date Alert Name Type % Chg
    20 DMA Resistance Bearish 0.00%
    Inside Day Range Contraction 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Fell Below 20 DMA Bearish -0.88%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -3.79%
    NR7 Range Contraction -3.79%
    Narrow Range Bar Range Contraction -3.79%
    Inside Day Range Contraction -3.79%
    50 DMA Resistance Bearish -4.11%
    Shooting Star Candlestick Bearish -4.11%
    Older End-of-Day Signals for YMAB ...

       Recent Intraday Alerts

    Alert Time
    Possible Inside Day about 13 hours ago
    Down 3% about 16 hours ago
    60 Minute Opening Range Breakdown about 17 hours ago
    20 DMA Resistance about 17 hours ago
    Down 2 % about 17 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    YMAB Chart by TradingView
    Basic chart:

    Profile

    Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody therapeutic products for cancer treatment in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system/leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. The company has a license and research collaboration agreement with Memorial Sloan-Kettering Cancer Center. Y-mAbs Therapeutics, Inc. was founded in 2015 and is headquartered in New York, New York.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Cancer Cancer Treatment Therapeutic Products Blastoma Brain Tumor Cancer Center Glioma Metastases Neuroblastoma Diffuse Intrinsic Pontine Glioma Kettering Cancer Center Memorial Sloan Refractory

    Is YMAB a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 26 Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024
    Apr 25 Y-mAbs to Present at 2024 ASCO Annual Meeting
    Apr 18 Y-mAbs Therapeutics (NASDAQ:YMAB) rises 9.6% this week, taking one-year gains to 161%
    Mar 28 Wall Street Analysts Think YmAbs Therapeutics (YMAB) Could Surge 31.33%: Read This Before Placing a Bet
    Mar 20 YmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains?
    Mar 14 Y-mAbs Therapeutics says CFO Kruse will resign from his role
    Mar 14 Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer
    Mar 12 Wall Street Analysts See a 31.41% Upside in Y-mAbs Therapeutics, Inc. (YMAB): Can the Stock Really Move This High?
    Mar 6 Cracking The Code: Understanding Analyst Reviews For Y-mAbs Therapeutics
    Mar 5 Are You Looking for a Top Momentum Pick? Why Y-mAbs Therapeutics, Inc. (YMAB) is a Great Choice
    See more YMAB news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 20.9
    52 Week Low 4.6
    Average Volume 346,796
    200-Day Moving Average 9.01
    50-Day Moving Average 15.73
    20-Day Moving Average 14.82
    10-Day Moving Average 15.06
    Average True Range 0.93
    RSI (14) 45.95
    ADX 13.9
    +DI 22.41
    -DI 19.27
    Chandelier Exit (Long, 3 ATRs) 14.69
    Chandelier Exit (Short, 3 ATRs) 16.14
    Upper Bollinger Bands 15.83
    Lower Bollinger Band 13.80
    Percent B (%b) 0.45
    BandWidth 13.74
    MACD Line -0.08
    MACD Signal Line -0.10
    MACD Histogram 0.027
    Fundamentals Value
    Market Cap 641.67 Million
    Num Shares 43.6 Million
    EPS -0.45
    Price-to-Earnings (P/E) Ratio -32.69
    Price-to-Sales 6.16
    Price-to-Book 5.71
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 15.87
    Resistance 3 (R3) 15.88 15.50 15.68
    Resistance 2 (R2) 15.50 15.21 15.50 15.61
    Resistance 1 (R1) 15.11 15.03 14.92 15.10 15.55
    Pivot Point 14.73 14.73 14.64 14.73 14.73
    Support 1 (S1) 14.33 14.44 14.15 14.32 13.87
    Support 2 (S2) 13.96 14.25 13.95 13.81
    Support 3 (S3) 13.56 13.96 13.74
    Support 4 (S4) 13.55